Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05115474 · ClinicalTrials.gov registry record
Study of Screening Brain MRIs in Stage IV Breast Cancer
A clinical trial of Triple Negative Breast Cancer and HER2-positive Breast Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 170
- Enrollment target
- 2
- Study locations
NCT05115474: Recruiting study of Triple Negative Breast Cancer and HER2-positive Breast Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05115474 is a study of Triple Negative Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 170 participants, below the 245-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (31% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05115474, a study of Triple Negative Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 170 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
Primary Outcome
Rate of brain metastasis by breast cancer subtype at baseline using MRI images.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Magnetic Resonance Imaging
Study Locations (2)
Florida
- Morton Plant Mease- Baycare - Clearwater
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2026-10 |
What NCT05115474 shows while recruiting
NCT05115474 is an observational study that tracks outcomes without assigning an intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 245-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (31% lower).
The record links to 3 conditions, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Resonance Imaging is the first listed.
NCT05115474 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05115474 about?
NCT05115474 is a clinical study titled "Study of Screening Brain MRIs in Stage IV Breast Cancer". The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
What is the current status of trial NCT05115474?
This trial is currently recruiting. The enrollment target is 170 participants. The study started on 2021-12-21. Estimated completion is 2026-10.
What conditions does trial NCT05115474 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer.
What interventions are being tested in trial NCT05115474?
The interventions under investigation include: Magnetic Resonance Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05115474?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05115474 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05115474's enrollment target sits among peer trials
170 35th of 118 higher than 84 of 118 other Triple Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
RECRUITING · Phase 2
-
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI